Crescent Biopharma (CBIO) Current Leases (2019 - 2026)
Crescent Biopharma (CBIO) posted quarterly Current Leases of $500000.0 for Q2 2026, up 136.97% year-over-year from $211000.0 in Q2 2025, and little changed quarter-over-quarter from $500000.0 in Q1 2026.
Crescent Biopharma (CBIO) Current Leases (2019 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Current Leases for 8 consecutive years, with $500000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Leases rose 136.97% year-over-year to $500000.0; the TTM figure through Jun 2026 stood at $500000.0 (up 136.97% YoY), while the FY2025 annual figure was $435000.0, changed N/A from the prior year.
- Current Leases steadied at $500000.0 in Q2 2026 per CBIO's latest filing, from $500000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.1 million in Q3 2022 and bottomed at $211000.0 in Q2 2025.
- Historically, Current Leases has averaged $653477.8 across 5 years, with a median of $641280.5 in 2023.
- Annual changes were most pronounced in 2024 — Current Leases plunged 65.03% — and 2026, when it surged 136.97%.
- Crescent Biopharma's Current Leases stood at $918555.0 in 2022, then retreated by 19.27% to $741558.0 in 2023, then slumped by 64.65% to $262133.0 in 2024, then jumped by 65.95% to $435000.0 in 2025, then rose by 14.94% to $500000.0 in 2026.
- Business Quant data shows CBIO's Current Leases at $500000.0 in Q2 2026, $500000.0 in Q1 2026, and $435000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 435,000.00 |
| Sep 30, 2025 | 417,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Sep 30, 2024 | 262,133.00 |
| Jun 30, 2024 | 448,775.00 |
| Mar 31, 2024 | 630,827.00 |
| Dec 31, 2023 | 741,558.00 |
| Sep 30, 2023 | 749,618.00 |
| Jun 30, 2023 | 820,243.00 |
| Mar 31, 2023 | 651,734.00 |
| Dec 31, 2022 | 918,555.00 |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.06 Mn |
| Mar 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 974,816.00 |
| Jun 30, 2021 | 948,787.00 |
| Mar 31, 2021 | 923,433.00 |